Technical Analysis for GTHX - G1 Therapeutics, Inc.

Grade Last Price % Change Price Change
F 21.73 -0.55% -0.12
GTHX closed down 0.55 percent on Wednesday, June 16, 2021, on 2.0 times normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat
Historical GTHX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Fell Below 50 DMA Bearish -0.55%
Bollinger Band Squeeze Range Contraction -0.55%
BB Squeeze + Upper Band Touch Range Contraction -0.55%
Upper Bollinger Band Touch Strength -0.55%
Crossed Above 50 DMA Bullish -4.48%
Older End-of-Day Signals for GTHX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 5 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Down 2 % about 6 hours ago
Fell Below 20 DMA about 6 hours ago
60 Minute Opening Range Breakout about 8 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Treatment Of Breast Cancer Hormones Her2 Her2/Neu Estrogen Protein Kinase Inhibitors Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant

Is GTHX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.0687
52 Week Low 10.81
Average Volume 913,474
200-Day Moving Average 19.36
50-Day Moving Average 22.02
20-Day Moving Average 21.61
10-Day Moving Average 21.78
Average True Range 1.04
ADX 17.57
+DI 19.99
-DI 17.72
Chandelier Exit (Long, 3 ATRs) 19.97
Chandelier Exit (Short, 3 ATRs) 23.60
Upper Bollinger Bands 22.62
Lower Bollinger Band 20.61
Percent B (%b) 0.56
BandWidth 9.29
MACD Line 0.09
MACD Signal Line 0.01
MACD Histogram 0.0795
Fundamentals Value
Market Cap 826.74 Million
Num Shares 38 Million
EPS -2.70
Price-to-Earnings (P/E) Ratio -8.04
Price-to-Sales 18.79
Price-to-Book 2.76
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.50
Resistance 3 (R3) 23.43 22.77 23.21
Resistance 2 (R2) 22.77 22.32 22.81 23.11
Resistance 1 (R1) 22.25 22.04 21.92 22.32 23.01
Pivot Point 21.59 21.59 21.43 21.63 21.59
Support 1 (S1) 21.07 21.14 20.74 21.14 20.45
Support 2 (S2) 20.41 20.86 20.45 20.35
Support 3 (S3) 19.89 20.41 20.26
Support 4 (S4) 19.96